LLY

724.86

-2.66%↓

NVO

122.65

-0.04%↓

MRK

125.78

+0.49%↑

ABBV

166.3

+0.95%↑

TMO

544.88

+0.67%↑

LLY

724.86

-2.66%↓

NVO

122.65

-0.04%↓

MRK

125.78

+0.49%↑

ABBV

166.3

+0.95%↑

TMO

544.88

+0.67%↑

LLY

724.86

-2.66%↓

NVO

122.65

-0.04%↓

MRK

125.78

+0.49%↑

ABBV

166.3

+0.95%↑

TMO

544.88

+0.67%↑

LLY

724.86

-2.66%↓

NVO

122.65

-0.04%↓

MRK

125.78

+0.49%↑

ABBV

166.3

+0.95%↑

TMO

544.88

+0.67%↑

LLY

724.86

-2.66%↓

NVO

122.65

-0.04%↓

MRK

125.78

+0.49%↑

ABBV

166.3

+0.95%↑

TMO

544.88

+0.67%↑

HomeStock ListACADIA Pharmaceuticals Inc

ACADIA Pharmaceuticals Inc

Closed

16.82 -1.23

Overview

Share price change

24h

Current

Min

16.6

Max

17.26

Key metrics

By Trading Economics

Income

111M

46M

Sales

19M

231M

EPS

0.28

Profit margin

19.822

Employees

597

EBITDA

93M

37M

Recommendations

By TipRanks

Recommendations

Buy

12 Months Forecast

+77.09 upside

Dividends

By Dow Jones

Next Earnings

6 May 2024

Market Stats

By TradingEconomics

Market Cap

23M

3B

Previous open

18.05

Previous close

16.82

Technical Score

By Trading Central

Confidence

Bullish Evidence

ACADIA Pharmaceuticals Inc Chart

Related News

19 Apr 2024, 19:03 UTC

Earnings

Trending: Procter & Gamble Earnings Top Wall Street Views

19 Apr 2024, 14:21 UTC

Earnings

Trending: American Express 1Q Profit Rises

19 Apr 2024, 13:44 UTC

Acquisitions, Mergers, Takeovers

Trending: Schneider Electric Confirms Deal Talks With Bentley Systems

19 Apr 2024, 21:32 UTC

Market Talk

Mexican Stocks Close Higher; Peso Recovers from Overnight Skid -- Market Talk

19 Apr 2024, 21:30 UTC

Top News

The Score: Tesla, United Airlines, Netflix and More Stocks That Defined the Week -- WSJ

19 Apr 2024, 21:30 UTC

Acquisitions, Mergers, Takeovers

Aon Expects to Complete Purchase of NFP On or About April 25, Subject to Satisfaction of Closing Conditions

19 Apr 2024, 21:04 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

19 Apr 2024, 21:04 UTC

Market Talk

S&P Raises Greece Outlook To Positive -- Market Talk

19 Apr 2024, 20:50 UTC

Market Talk

Financial Services Roundup: Market Talk

19 Apr 2024, 20:43 UTC

Top News

Stock Futures Slide, Oil Jumps After Israeli Strike on Iran -- Update

19 Apr 2024, 20:35 UTC

Earnings

These Stocks Moved the Most Today: Netflix, Super Micro, Paramount, American Express, DJT, Jabil, Tesla, and More -- Barrons.com

19 Apr 2024, 19:30 UTC

Market Talk

Crude Oil Futures End Volatile Week With Losses -- Market Talk

19 Apr 2024, 19:08 UTC

Market Talk

U.S. Natural Gas Futures Slip in Rangebound Trade -- Market Talk

19 Apr 2024, 18:48 UTC

Earnings

Alphabet, United Airlines, GE Vernova, and More Stocks Set to Climb -- Barrons.com

19 Apr 2024, 17:48 UTC

Market Talk
Earnings

P&G Sees Broader Applications For Fiber Spinning Technology -- Market Talk

19 Apr 2024, 17:17 UTC

Market Talk

U.S. Oil Rig Count Rises by Five to 511 -- Market Talk

19 Apr 2024, 17:15 UTC

Market Talk
Earnings

P&G Aims To Innovate Certain Baby Care Products -- Market Talk

19 Apr 2024, 17:08 UTC

Market Talk
Earnings

Procter & Gamble F3Q Sales Slightly Dented By Headwinds In International Markets -- Market Talk

19 Apr 2024, 17:05 UTC

Earnings

Netflix Stock Slides. Investors Fear Slowing Growth. -- Barrons.com

19 Apr 2024, 16:53 UTC

Earnings

Netflix Says It's Going Dark on Subscriber Numbers. Is the Model Maturing? -- Barrons.com

19 Apr 2024, 16:43 UTC

Market Talk

Global Equities Roundup: Market Talk

19 Apr 2024, 16:43 UTC

Earnings

The Bad News Heading Into AbbVie's First-Quarter Earnings Report -- IBD

19 Apr 2024, 16:43 UTC

Market Talk

SPDR Gold Rises as China Buyers Hedge Uncertainty -- Market Talk

19 Apr 2024, 16:20 UTC

Market Talk

Financial Services Roundup: Market Talk

19 Apr 2024, 16:20 UTC

Market Talk

Basic Materials Roundup: Market Talk

19 Apr 2024, 16:20 UTC

Market Talk
Earnings

Health Care Roundup: Market Talk

19 Apr 2024, 15:54 UTC

Earnings
Acquisitions, Mergers, Takeovers

Lennar Stock Is Underperforming. A Director Scooped Up Shares. -- Barrons.com

19 Apr 2024, 15:08 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

19 Apr 2024, 15:08 UTC

Market Talk

Canada Rate Cuts Still Seen in Cards After Budget Plans -- Market Talk

19 Apr 2024, 13:56 UTC

Market Talk
Earnings

Intuitive Surgical's Raised Procedure Outlook Is Positive Sign Given Various Drags -- Market Talk

Peer Comparison

Price change

ACADIA Pharmaceuticals Inc forecast

Price Target

By TipRanks

77.09% upside

12 Months Forecast

Average 30.23 USD  77.09%

High 39 USD

Low 19 USD

Based on 18 Wall Street analysts offering 12 month price targets forACADIA Pharmaceuticals Inc - Dist in the last 3 months.

Rating Consensus

By TipRanks

Buy

18 ratings

13

Buy

5

Hold

0

Sell

Technical Score

By Trading Central

16.6 / 17.61Support & Resistance

Short Term

Bullish Evidence

Intermediate Term

Strong Bearish Evidence

Long Term

Weak Bearish Evidence

Financials

Selling and administration expenses

Operating expenses

Pre-tax profit

Sales

Cost of sales

Gross profit on sales

EBITDA

Operating profit

$

About ACADIA Pharmaceuticals Inc

Acadia Pharmaceuticals Inc. is a biopharmaceutical company focused on the development and commercialization of medicines to address unmet medical needs in central nervous system disorders. The Company's product pipeline includes NUPLAZID (pimavanser), Trofinetide, ACP-044 and ACP-319. NUPLAZID (pimavanserin) is used for the treatment of hallucinations and delusions associated with Parkinson’s disease psychosis (PDP). NUPLAZID is a selective serotonin inverse agonist/antagonist, preferentially targeting 5-HT2A receptors with no appreciable affinity for dopaminergic, histaminergic, or muscarinic receptors. Trofinetide is a synthetic analog of the amino-terminal tripeptide of insulin-like growth factor 1 (IGF-1) designed to treat the core symptoms of Rett syndrome. ACP-044, is an orally administered, non-opioid analgesic being evaluated for the treatment of pain. ACP-319 is a positive allosteric modulator of the muscarinic receptor targeting M1 (M1 PAM).